SB 2237 amends section 1866G of the Social Security Act to push the expiration date for Acute Hospital Care at Home waiver flexibilities from 2025 to 2030 and to require an expanded follow‑up study and report by HHS. The study must analyze hospitals’ selection criteria for who receives hospital-at-home services and compare clinical outcomes, utilization, and costs between inpatient care and care delivered under the initiative.
Why it matters: the bill gives hospitals five more years of explicit waiver authority to furnish inpatient-level services in patients’ homes while forcing the federal government to assemble comparative evidence on safety, cost, staffing models, and equity. Those findings could determine whether the hospital-at-home model becomes a permanent Medicare policy, how payments are structured, and what oversight or guardrails policymakers impose.
At a Glance
What It Does
The bill amends Title XVIII to extend the Acute Hospital Care at Home waiver authority through 2030 and inserts a new requirement that HHS conduct and report a subsequent, comprehensive study by September 30, 2028. The study must compare quality, outcomes, costs, service mix, staffing, transfers, and socioeconomic characteristics between inpatient stays and hospital-at-home episodes and address selection bias where practicable.
Who It Affects
Primary effects fall on hospitals participating in CMS’s Acute Hospital Care at Home initiative, home health and post‑acute providers who support those episodes, Medicare beneficiaries who become eligible for inpatient-equivalent care at home, and HHS/CMS which must produce the analysis and report. Payers and state Medicaid programs will also watch the results for implications on cost and access.
Why It Matters
The extension preserves regulatory certainty for hospitals expanding home-based acute care while mandating the empirical work that payers and regulators need to judge safety, equity, and value. Practically, the bill buys time for program growth but forces a structured evidence-gathering exercise that could reshape payment rates, prior‑authorization approaches, and oversight rules.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB 2237 makes two concrete legal changes: it delays the statutory sunset for Medicare’s Acute Hospital Care at Home waiver flexibilities by five years, and it adds a new, targeted follow‑up study requirement for HHS. The extension is mechanical — changing the date in section 1866G(a)(1) from 2025 to 2030 — but it matters because it keeps the waiver authority in place while hospitals scale programs and develop operational models.
The added study is detailed and prescriptive. HHS must, by September 30, 2028, analyze the selection criteria hospitals use to decide which patients qualify for at‑home acute care and run comparative analyses across participating hospitals and against comparable non‑participating hospitals.
The Secretary’s analysis must cover a wide set of parameters: clinical outcomes (mortality, readmissions, length of stay), infection and transfer rates, staffing composition (including contracted labor and nurse ratios), the quantity and intensity of in-home and virtual services, the mix of diagnoses treated, and the costs hospitals incur for inpatient versus at‑home care (staffing, equipment, food, prescriptions and other services).The bill also requires HHS to examine patient mix and equity-related variables—race, income, housing status, dual eligibility, and geographic proximity to the brick‑and‑mortar facility—and to compare patients who enter hospital‑at‑home directly from an ED with those moved from inpatient beds. Recognizing methodological limits, the statute directs the Secretary to address selection bias to the extent practicable and to submit a report of the study to the House Ways and Means Committee and the Senate Finance Committee on the same September 30, 2028 deadline.
That report will provide the primary federal evidence base for any future decision on whether to make these flexibilities permanent or to reform payment and oversight approaches.
The Five Things You Need to Know
The bill amends 42 U.S.C. 1395cc–7 (section 1866G) by replacing the 2025 sunset with 2030, extending waiver authority five years.
It creates a new subsection (c) requiring a study and report due to Congress on September 30, 2028, with specific analytic tasks for HHS.
The required study must compare outcomes and utilization across participating and non‑participating hospitals, including readmission timing and rates, hospital mortality, infection rates, transfers between home and hospital, and length of stay.
The Secretary must analyze costs to hospitals for inpatient versus hospital‑at‑home episodes—covering staffing, equipment, food, prescriptions, and other services—and evaluate the mix and intensity of in‑person and virtual contacts.
The statute mandates socioeconomic and access analyses (race/ethnicity, income, housing, dual‑eligibility, and distance to facility) and an explicit comparison of patients who enter the program from the ED versus from inpatient status, with an instruction to control for selection bias where practicable.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s name: the "Hospital Inpatient Services Modernization Act." This is a standard drafting device with no substantive effect on program rules, but it signals the bill’s framing: modernizing inpatient services by enabling home-based delivery.
Extend waiver authority through 2030
Substitutes ‘‘2030’’ for ‘‘2025’’ in section 1866G(a)(1). The practical implication is calendar certainty: hospitals and health systems operating under CMS waivers retain statutory cover to furnish inpatient-level care at home for an additional five years absent further action. For compliance teams, this removes near-term regulatory expiration risk that could otherwise force rapid program wind‑downs or contractual reversions.
Subsequent study and required report to Congress
Inserts a detailed new study mandate. The Secretary must analyze hospitals’ patient-selection criteria and run multi-dimensional comparisons covering clinical outcomes, readmissions (including beyond 30 days), mortality, length of stay, infection and transfer rates, staffing mixes (including contracted labor), service quantity/intensity (in‑person vs virtual), cost components, diagnosis-related groups treated, socioeconomic attributes of patients, and differences for ED-originating versus inpatient-originating participants. The provision also requires HHS to address selection bias to the extent practicable and to deliver its report to the House Ways and Means and Senate Finance Committees by September 30, 2028 — creating a hard deadline for consolidated federal evidence.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Participating hospitals and health systems — they gain five more years of explicit waiver authority to scale hospital‑at‑home programs, protecting capital investments and contractual arrangements with home health vendors and technology providers while policy evidence accumulates.
- Medicare beneficiaries suitable for acute home care — eligible patients may continue to access inpatient‑level services at home (avoiding traditional hospital stays) where the program is available, potentially improving comfort and reducing exposure to facility‑based harms.
- Policymakers and regulators — HHS, CMS, and Congressional committees will receive a prescriptive, multi‑metric evidence package intended to inform permanent rulemaking or payment reforms, improving the quality of future policy decisions.
Who Bears the Cost
- Hospitals and health systems — they must continue investing in operational infrastructure, data collection, and potentially higher marginal costs for home services and staffing; some systems will also face administrative burden to supply HHS with the detailed data the study requires.
- Home health agencies and community providers — increased demand for in‑home nursing, durable medical equipment, and virtual monitoring may strain capacity and require upfront hiring, training, or new contracts, shifting costs and operational risk to these providers.
- HHS/CMS — the department must design and execute a complex comparative study, which requires analytic resources, standardized data requests, and methodological work to control for selection bias; this imposes administrative costs and a significant analytic task on the agencies.
Key Issues
The Core Tension
The bill pits two legitimate objectives against one another: preserve experimental, patient‑centered delivery options and encourage program growth (by extending waiver authority), while demanding high‑quality evidence to ensure those options are as safe, equitable, and cost‑effective as inpatient care. Speed and access on one side; robust, causally credible evaluation and appropriate oversight on the other — and the statute gives HHS responsibility for resolving how much evidence is 'good enough' to justify permanence.
The statute orders a broad comparative study but leaves major methodological choices to the Secretary. Translating the listed metrics into reliable causal inferences will be difficult: hospitals choose which patients to treat at home, and administrative data typically lack the clinical nuance to fully account for those selection decisions.
The statutory instruction to address selection bias “to the extent practicable” provides latitude; HHS may rely on risk‑adjustment, propensity scoring, or facility‑level comparisons, each carrying different assumptions and limits.
Other implementation challenges include standardizing cost accounting across hospitals (what counts as a hospital cost versus a community or family burden), collecting granular staffing and service‑delivery data (contracted labor, virtual contacts), and protecting patient privacy while assembling socioeconomic and clinical linkages. The bill requires comparisons with non‑participating hospitals and examines transfers and readmissions beyond 30 days, which will necessitate cross‑setting data sharing and possibly new data‑use agreements.
Finally, extending the waiver until 2030 reduces short‑term regulatory risk but also delays a definitive policy choice: if the study is inconclusive or contested, hospitals could continue operating under temporary authority without a clear transition to a permanent framework.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.